Trial Profile
Phase I/II Study of Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent Glioblastoma (RGBM)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 23 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Jun 2024.
- 24 Aug 2023 Status changed from suspended to recruiting.
- 03 Jul 2023 Planned End Date changed from 15 Jun 2024 to 15 Dec 2024.